Patent NZ-597528-A (NZ)
Title: Inhibitors of flaviviridae viruses
Inventor: LEW WILLARD
IPC: A61K31/381
Filed: 2010-07-19
Abstract: Disclosed are 5-(3,3-dimethyl-but-1-ynyl)-3-{ (cyclohexylcarbonyl)-amino} -thiophene-2-carboxylic acid derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of optionally substituted alkyl, and optionally substituted saturated cycloalkyl; R2 is optionally substituted saturated or partially unsaturated cycloalkyl; wherein, each substituted R2 is substituted with one or more members independently selected from the group consisting of alkyl and OH; R3 is selected from the group consisting of optionally substituted alkylene, saturated cycloalkylene, substituted saturated cycloalkylene, optionally substituted arylene, and optionally substituted heterocyclylene; L is selected from the group consisting of O, S, S(O), and S(O)2; Het is an optionally substituted 3-12 membered heterocyclyl or optionally substituted 5-10 membered heteroaryl, wherein said 5 optionally substituted 3-12 membered heterocyclyl or optionally substituted 5-10 membered heteroaryl comprises one to four heteroatoms selected from O, S, or N; and wherein the remaining substituents are as defined herein. Also disclosed are representative compounds including 5-(3,3-dimethyl-but-1-ynyl)-3-{ (trans-4-methyl-cyclohexanecarbonyl)-[trans-4-(6-methyl-pyridazin-3-yloxy)-cyclohexyl]-amino} -thiophene-2-carboxylic acid, 5-(3,3-dimethyl-but-1-ynyl)-3-{ (trans-4-methyl-cyclohexanecarbonyl)-[trans-4-(6-oxo-1,6-dihydropyridazin-3-yloxy)-cyclohexyl]-amino} -thiophene-2-carboxylic acid, 5-(3,3-dimethyl-but-1-ynyl)-3-{ (trans-4-methyl-cyclohexanecarbonyl)-[trans-4-(4-pyrrolidin-1-ylmethyl-pyridin-2-yloxy)-cyclohexyl]-amino} -thiophene-2-carboxylic acid, 5-(3,3-dimethyl-but-1-ynyl)-3-[(trans-4-methyl-cyclohexanecarbonyl)-[1-(S)-methyl-3-(4-pyrrolidin-1-yl-methyl-pyridin-2-yloxy)-propyl]-amino]-thiophene-2-carboxylic acid, 3-(N-(4-(4-cyclopropyl-4H-1,2,4-triazol-3-ylthio)cyclohexyl)-4-methylcyclohexanecarboxamido)-5-(3,3-dimethylbut-1-ynyl)thiophene-2-carboxylic acid, 5-(3,3-dimethylbut-1-ynyl)-3-(4-methyl-N-(4-(1-methyl-1H-tetrazol-5-ylthio)cyclohexyl)cyclohexanecarboxamido)thiophene-2-carboxylic acid, 5-(3,3-dimethylbut-1-ynyl)-3-(4-methyl-N-(4-(1-methyl-1H-tetrazol-5-ylsulfonyl)cyclohexyl)cyclohexanecarboxamido)thiophene-2-carboxylic acid, 5-(3,3-dimethylbut-1-ynyl)-3-(4-methyl-N-(4-(pyridazin-4-yloxy)cyclohexyl)cyclohexanecarboxamido)thiophene-2-carboxylic acid, 5-(3,3-dimethylbut-1-ynyl)-3-((1R,4R)-4-methyl-N-((1R,4R)-4-(tetrahydro-2H-pyran-4-yloxy)cyclohexyl)cyclohexanecarboxamido)thiophene-2-carboxylic acid and 5-(3,3-dimethyl-but-1-ynyl)-3-{ (1R)-4-methylcyclohex-3-enecarbonyl)-[4-(tetrahydro-furan-3(S)-yloxy)-trans-cyclohexyl]-amino} -thiophene-2-carboxylic acid and 3-[[4-(4-dimethylaminomethyl-pyridin-2-yloxy)-cyclohexyl]-(4-methylene-cyclohexanecarbonyl)-amino]-5-(3,3-dimethyl-but-1-ynyl)-thiophene-2-carboxylic acid. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above, and a pharmaceutically acceptable carrier or excipient, for treating a viral infection caused by a Hepatitis C virus.